{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:57:00Z","timestamp":1777658220910,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"EU"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ejca.2020.10.006","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T13:04:00Z","timestamp":1605013440000},"page":"218-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4043-3279","authenticated-orcid":false,"given":"Luca","family":"Mazzarella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6464-509X","authenticated-orcid":false,"given":"Silvia","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Belli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno Achutti","family":"Duso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.10.006_bib1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.10.006_bib2","first-page":"173","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis","author":"Barroso-sousa","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.10.006_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy\u00a0: ESMO clinical practice guidelines for diagnosis , treatment and follow-up \u2020 clinical practice guidelines","volume":"28","author":"Guidelines","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.10.006_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"ScienceDirect Neurological adverse events associated with immune checkpoint inhibitors\u00a0: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.10.006_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2020.10.006_bib6","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.006_bib7","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2020.10.006_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1084\/jem.185.2.317","article-title":"Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures","volume":"185","author":"Winzler","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2020.10.006_bib9","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1200109","article-title":"Role of CD25+ dendritic cells in the generation of Th17 autoreactive T cells in autoimmune experimental uveitis","volume":"188","author":"Liang","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2020.10.006_bib10","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.2337\/db08-1113","article-title":"Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice","volume":"58","author":"Emamaullee","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ejca.2020.10.006_bib11","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ejca.2020.10.006_bib12","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.4049\/jimmunol.1501339","article-title":"Autoreactive T cells from patients with myasthenia gravis are characterized by elevated IL-17, IFN-gamma, and GM-CSF and diminished IL-10 production","volume":"196","author":"Cao","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2020.10.006_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1749-6632.2012.06791.x","article-title":"Defects of immunoregulatory mechanisms in myasthenia gravis: role of IL-17","volume":"1274","author":"Gradolatto","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejca.2020.10.006_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2020.10.006_bib15","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.4049\/jimmunol.1300083","article-title":"The influence of T cell Ig mucin-3 signaling on central nervous system autoimmune disease is determined by the effector function of the pathogenic T cells","volume":"190","author":"Lee","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2020.10.006_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2020.10.006_bib17","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.10.006_bib18","first-page":"1","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors\u00a0: a pharmacovigilance study","author":"Johnson","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2020.10.006_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.10.006_bib20","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8206.1","article-title":"Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms","volume":"5","author":"Phillips","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.ejca.2020.10.006_bib21","first-page":"11","article-title":"Targeting the IL-17 \u2013 T H 17 pathway","volume":"14","author":"Bartlett","year":"2015","journal-title":"Nat Publ Gr"},{"key":"10.1016\/j.ejca.2020.10.006_bib22","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2020.10.006_bib23","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade","volume":"376","author":"Esfahani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.10.006_bib24","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2337\/db07-0226","article-title":"Targeting of pancreatic glia in type 1 diabetes","volume":"57","author":"Tsui","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.ejca.2020.10.006_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2019.03.002","article-title":"Immune checkpoint inhibitor - associated hypophysitis - World Health Organisation VigiBase report analysis","volume":"113","author":"Guerrero","year":"2019","journal-title":"Eur J Canc"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920310625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920310625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:30:32Z","timestamp":1760733032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920310625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":25,"alternative-id":["S0959804920310625"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.10.006","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}